| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.410130508 |
| P698 | PubMed publication ID | 6191621 |
| P50 | author | Edward D. Bird | Q84176647 |
| P2093 | author name string | Lorenz LJ | |
| Martin JB | |||
| Aronin N | |||
| Sagar SM | |||
| Leeman SE | |||
| Cooper PE | |||
| P2860 | cites work | Neostriatal administration of somatostatin: differential effect of small and large doses on behavior and motor control | Q48303468 |
| P433 | issue | 5 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 519-526 | |
| P577 | publication date | 1983-05-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Somatostatin is increased in the basal ganglia in Huntington disease | |
| P478 | volume | 13 |
| Q52026807 | A long-term follow-up study of cerebrospinal fluid somatostatin in delirium. |
| Q40780751 | Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention |
| Q33703905 | Are there multiple pathways in the pathogenesis of Huntington's disease? |
| Q39472153 | Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness. An overview |
| Q45293741 | Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum |
| Q52064890 | Cerebrospinal fluid somatostatin in delirium. |
| Q52056782 | Cerebrospinal fluid somatostatin in delirium. II. Changes at the acute stage and at one year follow-up. |
| Q42480737 | Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes. |
| Q42513647 | Cholecystokinin content in the basal ganglia in Huntington's disease. The expression of cholecystokinin immunoreactivity in striatal grafts to ibotenic acid-lesioned rat striatum |
| Q82676429 | Colocalization of somatostatin receptors with DARPP-32 in cortex and striatum of rat brain |
| Q39480484 | Dementia in movement disorders. |
| Q48634539 | Depletion of striatal somatostatin by local cysteamine injection |
| Q70648797 | Determination of neuropeptides in discrete regions of the rat brain by high-performance liquid chromatography with electrochemical detection |
| Q36833285 | Does the absence of clinical expression of choreoathetosis, despite severe striatal atrophy, correlate with plasticity of neuropeptide synthesis? |
| Q48657115 | Effects of neuroleptic drugs on brain somatostatin-like-immunoreactivity |
| Q48421566 | Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat. |
| Q36870168 | Expression of NMDA Receptor-1 (NR1) and Huntingtin in Striatal Neurons Which Colocalize Somatostatin, Neuropeptide Y, and NADPH Diaphorase: A Double-Label Histochemical and Immunohistochemical Study |
| Q61714030 | HPLC analysis of somatostatin related peptides in putamen of Huntington's Disease patients |
| Q40080656 | Huntington's disease. A decade of progress. |
| Q37003956 | Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. |
| Q40111573 | Implications of neuropeptides in neurological diseases |
| Q70068537 | Localization of immunoreactive GABA and enkephalin and NADPH-diaphorase-positive neurons in fetal striatal grafts in the quinolinic-acid-lesioned rat neostriatum |
| Q64269587 | Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington’s Disease Mice |
| Q39480297 | Neuropeptides and the pathology of Huntington's disease |
| Q45298042 | Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: an immunohistochemical study |
| Q39498368 | Neuropeptides, behavior, and aging |
| Q37167222 | Neurotransmitter Receptors in Human Brain Diseases |
| Q40093769 | Neurotransmitters in the basal ganglia |
| Q44588510 | Physiological release of striatal acetylcholine (in vivo): effect of somatostatin on dopaminergic-cholinergic interaction |
| Q39750104 | Physiology of peptides in basal ganglia. |
| Q43770051 | Postmortem stability of somatostatin in brain tissue |
| Q42052839 | Quinolinic acid stimulates somatostatin gene expression in cultured rat cortical neurons |
| Q45305415 | Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease |
| Q48383756 | Regulation of the preprosomatostatin gene by cyclic-AMP in cerebrocortical neurons |
| Q34384772 | Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid |
| Q42448489 | Selective increase in somatostatin mRNA expression in human basal ganglia in Parkinson's disease |
| Q46592729 | Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity |
| Q36926831 | Somatostatin in the dentate gyrus |
| Q42516711 | Somatostatin modulates Ca2+ currents in neostriatal neurons |
| Q34017941 | Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice |
| Q28298522 | Substance P and substance P receptor histochemistry in human neurodegenerative diseases |
| Q72580799 | The effect of somatostatin on striatal catecholamines |
| Q42503236 | Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease |
Search more.